Phase I/II study concomitant high-dose radio-immuno- and chemotherapy with simultaneous application of Zevalin and BEAM [busulfan, cytarabine, etoposide, melphalan] followed by autologous peripheral stem cell transplantation in relapsed and refractory CD 20+ non-Hodgkin's lymphoma.

Trial Profile

Phase I/II study concomitant high-dose radio-immuno- and chemotherapy with simultaneous application of Zevalin and BEAM [busulfan, cytarabine, etoposide, melphalan] followed by autologous peripheral stem cell transplantation in relapsed and refractory CD 20+ non-Hodgkin's lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2013

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Busulfan; Cytarabine; Etoposide; Melphalan
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms escZ-BEAM
  • Most Recent Events

    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Jun 2008 Preliminary results presented at ASCO 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top